Stories > Amneal Resubmits IPX203 for Parkinson’s Disease

Amneal Resubmits IPX203 for Parkinson’s Disease

Advancements in Cancer Treatment and Mar...

Advancements in Huntington's Disease Tre...

Advancements in Psychiatric Treatments

AMX0035 for PSP: Phase 3 Trial Commences

ANJESO Drug Insight and Market Forecast

ARMGO Pharma's Positive Trial Results